metformin has been researched along with pf 04971729 in 20 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 12 (60.00) | 24.3611 |
2020's | 8 (40.00) | 2.80 |
Authors | Studies |
---|---|
Amin, NB; Jain, SM; Lee, DS; Nucci, G; Rusnak, JM; Wang, X | 1 |
Charbonnel, B; Darekar, A; Frias, J; Huyck, S; Lauring, B; Páll, D; Pascu, R; Rosenstock, J; Saur, D; Shi, H; Terra, SG | 1 |
Amorin, G; Dagogo-Jack, S; Eldor, R; Engel, SS; Golm, G; Hille, D; Huyck, S; Johnson, J; Lauring, B; Liao, Y; Liu, J; Mancuso, JP; Terra, SG | 1 |
Eldor, R; Engel, SS; Golm, G; Huyck, SB; Johnson, J; Lauring, B; Mancuso, JP; Pratley, RE; Qiu, Y; Raji, A; Sunga, S; Terra, SG | 1 |
Markham, A | 1 |
Alvey, C; Cutler, DL; Dawra, VK; Hickman, A; Krishna, R; Liang, Y; Sahasrabudhe, V; Saur, D; Shi, H; Terra, SG; Zhou, S | 1 |
Bass, A; Dawra, VK; Fediuk, DJ; Hickman, A; Krishna, R; Liang, Y; Matschke, K; Sahasrabudhe, V; Shi, H; Terra, SG; Zhou, S | 1 |
Charbonnel, B; Darekar, A; Gallo, S; Goldman, A; Huyck, S; Lauring, B; Shi, H; Terra, SG | 1 |
Frias, JP | 1 |
Bass, A; Cutler, D; Dawra, VK; Hickman, A; Liang, Y; Sahasrabudhe, V; Shi, H; Terra, SG; Zhou, S | 1 |
Huyck, S; Ji, L; Lauring, B; Liu, S; Liu, Y; Miao, H; Mu, Y; Pan, S; Qiu, Y; Terra, SG; Wang, W; Xie, Y; Yan, P; Yang, M | 1 |
Kuhad, A; Razdan, K; Sharma, R | 1 |
Bass, A; Dawra, VK; Hickman, A; Krishna, R; Liang, Y; Pelletier, K; Sahasrabudhe, V; Shi, H; Terra, SG; Wei, H; Zhou, S | 1 |
Scheen, AJ | 1 |
Dawra, VK; Hickman, A; Krishna, R; Matschke, K; Pelletier, K; Sahasrabudhe, V; Shi, H; Zhou, S | 1 |
Gallo, S; Gantz, I; Greenberg, M; Lingvay, I; Liu, J; Shi, H | 1 |
Athyros, VG; Boutari, C; Karagiannis, A | 1 |
Cannon, CP; Cherney, DZI; Cosentino, F; Dagogo-Jack, S; Frederich, R; Gantz, I; Liu, J; Mancuso, JP; Pong, A; Pratley, RE | 1 |
Cannon, CP; Cater, NB; Cherney, DZI; Cosentino, F; Dagogo-Jack, S; Frederich, R; Maldonado, M; Mancuso, JP; McGuire, DK; Pratley, RE; Wang, S | 1 |
Cannon, CP; Cherney, DZI; Cosentino, F; Dagogo-Jack, S; Frederich, R; Gantz, I; Liu, J; Masiukiewicz, U; Pratley, RE; Shi, H | 1 |
3 review(s) available for metformin and pf 04971729
Article | Year |
---|---|
Ertugliflozin: First Global Approval.
Topics: Blood Glucose; Bridged Bicyclo Compounds, Heterocyclic; Diabetes Mellitus, Type 2; Drug Approval; Humans; Hypoglycemic Agents; Metformin; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; United States; United States Food and Drug Administration | 2018 |
Fixed-dose combination of ertugliflozin and metformin hydrochloride for the treatment of type 2 diabetes.
Topics: Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Combinations; Humans; Hypoglycemic Agents; Metformin; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Treatment Outcome | 2019 |
Ertugliflozin for the treatment of type 2 diabetes.
Topics: Bridged Bicyclo Compounds, Heterocyclic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Sitagliptin Phosphate; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
14 trial(s) available for metformin and pf 04971729
Article | Year |
---|---|
Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Bridged Bicyclo Compounds, Heterocyclic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Genital Diseases, Female; Genital Diseases, Male; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Mycoses; Sitagliptin Phosphate; Sodium-Glucose Transport Proteins; Urinary Tract Infections | 2015 |
Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET).
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Bone Density; Bridged Bicyclo Compounds, Heterocyclic; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss; Young Adult | 2018 |
Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study.
Topics: Blood Pressure; Bridged Bicyclo Compounds, Heterocyclic; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial.
Topics: Aged; Body Mass Index; Bridged Bicyclo Compounds, Heterocyclic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Overweight; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Assessment of the Drug Interaction Potential of Ertugliflozin With Sitagliptin, Metformin, Glimepiride, or Simvastatin in Healthy Subjects.
Topics: Adolescent; Adult; Bridged Bicyclo Compounds, Heterocyclic; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Interactions; Drug Therapy, Combination; Female; Glucuronosyltransferase; Healthy Volunteers; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Sulfonylurea Compounds; UDP-Glucuronosyltransferase 1A9; Young Adult | 2019 |
Effect of Food on the Pharmacokinetics of Ertugliflozin and Its Fixed-Dose Combinations Ertugliflozin/Sitagliptin and Ertugliflozin/Metformin.
Topics: Adult; Bridged Bicyclo Compounds, Heterocyclic; Cross-Over Studies; Dietary Fats; Drug Combinations; Female; Food-Drug Interactions; Healthy Volunteers; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Young Adult | 2019 |
Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial.
Topics: Aged; Blood Glucose; Bone Density; Bridged Bicyclo Compounds, Heterocyclic; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Mycoses; Reproductive Tract Infections; Sulfonylurea Compounds; Vulvovaginitis | 2019 |
A PK/PD study comparing twice-daily to once-daily dosing regimens of ertugliflozin in healthy subjects
.
Topics: Adolescent; Adult; Bridged Bicyclo Compounds, Heterocyclic; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Healthy Volunteers; Humans; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Young Adult | 2019 |
Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia.
Topics: Aged; Asia, Eastern; Bridged Bicyclo Compounds, Heterocyclic; Diabetes Mellitus, Type 2; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Metformin; Middle Aged; Philippines; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Bioequivalence of Ertugliflozin/Metformin Fixed-Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components.
Topics: Adolescent; Adult; Bridged Bicyclo Compounds, Heterocyclic; Cross-Over Studies; Drug Combinations; Fasting; Female; Healthy Volunteers; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Tablets; Therapeutic Equivalency; Young Adult | 2020 |
Bioequivalence of Metformin in Ertugliflozin/Metformin Fixed-Dose Combination Tablets to Canadian-Sourced Metformin Coadministered With Ertugliflozin Under Fasted and Fed States.
Topics: Adult; Area Under Curve; Bridged Bicyclo Compounds, Heterocyclic; Canada; Cross-Over Studies; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Tablets; Therapeutic Equivalency; Young Adult | 2021 |
Efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus and established cardiovascular disease using insulin: A VERTIS CV substudy.
Topics: Blood Glucose; Bridged Bicyclo Compounds, Heterocyclic; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2021 |
Cardiorenal Outcomes With Ertugliflozin by Baseline Metformin Use: Post Hoc Analyses of the VERTIS CV Trial.
Topics: Bridged Bicyclo Compounds, Heterocyclic; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV.
Topics: Bridged Bicyclo Compounds, Heterocyclic; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Metformin; Sodium-Glucose Transporter 2 Inhibitors | 2023 |
3 other study(ies) available for metformin and pf 04971729
Article | Year |
---|---|
[Ertugliflozin alone and in fixed-dose combinations : «pass of three»].
Topics: Bridged Bicyclo Compounds, Heterocyclic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin | 2020 |
Ertugliflozin + metformin as a treatment option for type 2 diabetes.
Topics: Bridged Bicyclo Compounds, Heterocyclic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose-lowering agent: An analysis from VERTIS CV.
Topics: Bridged Bicyclo Compounds, Heterocyclic; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucose; Humans; Hypoglycemic Agents; Insulin; Metformin; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2022 |